Combination chemotherapy and immunomodulatory therapy
This page covers all Combination chemotherapy and immunomodulatory therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Proteasome (bortezomib), DNA (melphalan), glucocorticoid receptor (prednisone), cereblon (thalidomide).
Targets
Phase 3 pipeline (2)
- Cyclophosphamide, Prednisone, Lenalidomide · Fondazione EMN Italy Onlus · Oncology
This combination uses cyclophosphamide and prednisone as immunosuppressive/chemotherapy agents alongside lenalidomide, an immunomodulatory drug that enhances T-cell proliferation and has anti-angiogenic properties. - Bortezomib, Melphalan, Prednisone, Thalidomide · Fondazione EMN Italy Onlus · Oncology
This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation.